1. Home
  2. REAL vs PRQR Comparison

REAL vs PRQR Comparison

Compare REAL & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The RealReal Inc.

REAL

The RealReal Inc.

HOLD

Current Price

$16.21

Market Cap

1.7B

ML Signal

HOLD

Logo ProQR Therapeutics N.V.

PRQR

ProQR Therapeutics N.V.

HOLD

Current Price

$2.17

Market Cap

250.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REAL
PRQR
Founded
2011
2012
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
250.7M
IPO Year
2019
2014

Fundamental Metrics

Financial Performance
Metric
REAL
PRQR
Price
$16.21
$2.17
Analyst Decision
Buy
Strong Buy
Analyst Count
8
7
Target Price
$15.29
$8.14
AVG Volume (30 Days)
2.5M
639.0K
Earning Date
11-10-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$662,789,000.00
$18,859,556.00
Revenue This Year
$17.10
N/A
Revenue Next Year
$10.90
$19.56
P/E Ratio
N/A
N/A
Revenue Growth
14.30
N/A
52 Week Low
$4.61
$1.07
52 Week High
$16.33
$3.10

Technical Indicators

Market Signals
Indicator
REAL
PRQR
Relative Strength Index (RSI) 68.66 49.04
Support Level $15.13 $2.03
Resistance Level $16.08 $2.25
Average True Range (ATR) 0.77 0.17
MACD 0.10 0.00
Stochastic Oscillator 90.47 37.36

Price Performance

Historical Comparison
REAL
PRQR

About REAL The RealReal Inc.

The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.

About PRQR ProQR Therapeutics N.V.

ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.

Share on Social Networks: